Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 0186

X
Drug Profile

AZD 0186

Alternative Names: AZD-0186

Latest Information Update: 07 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 02 Oct 2023 Pharmacokinetics data from a preclinical studies for type 2 diabetes mellitus presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
  • 31 Jul 2023 Discontinued - Phase-I for Type 2 diabetes mellitus (In volunteers) in USA (PO) before July 2023 (AstraZeneca Pipeline, July 2023)
  • 10 May 2023 AstraZeneca terminates a phase I trial in type 2 diabetes mellitus (In volunteers) in USA (PO) due to the overall data profile obtained from this study which did not demonstrate sufficient differentiation to surpass the current standard of care (NCT05694741)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top